AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial performance, product development, and market expansion, particularly with the EnCompass Clamp and AtriClip devices. The Q&A section highlights challenges like U.K. budget issues but emphasizes strategic investments and clinical trials. Despite some softer Clip sales, the company's guidance remains optimistic, and increased R&D leverage is expected. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
Key Financial Performance
Total Revenue $534 million, reflecting 15% growth over 2024. The growth was driven by newer product launches, continued adoption of therapies, and operational execution.
Adjusted EBITDA $61.8 million, an improvement of $30.6 million from 2024. This was due to operational leverage and favorable product mix.
Cash Generated $45 million in 2025. This reflects efficient capital management and financial flexibility.
Gross Margin 75%, an increase of 29 basis points from 2024. This was driven by favorable product mix and production efficiencies.
U.S. Revenue $435.4 million, a 13.7% increase over 2024. Growth was supported by product launches in pain management and open appendage management, and adoption of the EnCompass Clamp.
International Revenue $99.2 million, a 20.2% increase on a reported basis and 17.5% on a constant currency basis. Growth was robust across major regions except for the U.K., which faced funding and reimbursement challenges.
Pain Management Revenue $81.9 million in the U.S., a 32.5% increase over 2024. Growth was driven by the adoption of the cryoSPHERE MAX probe.
Open Ablation Revenue $143.8 million in the U.S., a 16.3% growth over 2024. Growth was driven by the EnCompass Clamp.
Open Appendage Management Revenue $178.1 million in the U.S., a 17.5% increase over 2024. Growth was driven by the adoption of the AtriClip FLEX-Mini device.
Minimally Invasive Ablation Revenue $31.5 million in the U.S., a 31.2% decline over 2024. The decline was due to the prioritization of PFA catheters over the company's devices.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: Launched cryoSPHERE MAX Probe, AtriClip FLEX-Mini device, AtriClip PRO Mini, and cryoXT PRO in 2025. These products contributed to revenue growth and operational improvements.
Product Development: Advanced development of dual energy EnCompass Clamp, combining RF ablation and PFA for improved speed and flexibility. Completed first-in-human treatments in December 2025.
Market Expansion: Achieved 15% revenue growth in 2025, driven by product launches and adoption. Expanded U.S. accounts for cryoSPHERE MAX to 500 and EnCompass Clamp to 830 accounts globally.
International Growth: International revenue grew 20.2% in 2025, with strong performance in appendage management and open ablation franchises. However, U.K. sales declined due to NHS funding issues.
Operational Efficiencies: Improved gross margin to 75% in 2025 due to favorable product mix and production efficiencies. SG&A expenses grew below revenue growth, showing leverage.
Clinical Trials: Completed enrollment for LeAAPS trial with 6,500 patients and initiated BoxX-NoAF trial for reducing postoperative Afib. Progressed on site initiation and enrollment for BoxX-NoAF.
Strategic Shifts: Focused on preventative treatment of Afib and related complications through clinical trials (LeAAPS and BoxX-NoAF). Shifted towards building standards of care in cardiac surgery and pain management.
Hybrid AF Therapy: Faced challenges in minimally invasive Afib treatment due to PFA catheter adoption. Committed to stabilizing and scaling Hybrid AF therapy for advanced Afib patients.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and reimbursement uncertainty in the U.K.: The decline in sales in the U.K. due to ongoing funding and reimbursement uncertainty with the National Health Service impacted international revenue growth in the fourth quarter of 2025.
Pressure on minimally invasive ablation and MIS appendage management: The Hybrid AF therapy faced significant headwinds due to the dominance of PFA catheters in the U.S., leading to a 31.2% decline in U.S. MIS revenue in 2025. This trend is expected to continue in 2026, albeit at a moderated rate.
Postoperative Afib complications: Up to 50% of cardiac surgery patients without preexisting Afib develop postoperative Afib, leading to worse clinical outcomes and higher healthcare costs, estimated at over $2 billion annually in the U.S.
Underpenetration of pre-op Afib treatment: Despite the EnCompass Clamp's success, the treatment of pre-op Afib patients undergoing cardiac surgery remains vastly underpenetrated, representing a missed opportunity for growth.
Dependence on clinical trial outcomes: The success of key clinical trials like LeAAPS and BoxX-NoAF is critical for market expansion and future growth. Delays or unfavorable outcomes could adversely impact strategic objectives.
Market competition in Hybrid AF therapy: The Hybrid AF therapy is under pressure from competing PFA catheter technologies, which dominate the standalone Afib treatment market, creating challenges for adoption and revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Growth: Reaffirmed guidance for 2026 revenue growth of 12% to 14%, translating to $600 million to $610 million in revenue.
Pain Management Growth: Anticipated to lead growth in 2026, driven by cryoSPHERE MAX and cryoXT devices, with cryoXT expected to contribute more meaningfully in the back half of 2026.
Open Appendage Management and Open Ablation Growth: Expected to grow in line with the overall guidance range of 12% to 14%.
Minimally Invasive Ablation and MIS Appendage Management: Expected to decline in revenue in 2026, but at a moderated rate compared to 2025.
Geographic Growth: Both U.S. and international businesses expected to deliver growth at more closely aligned rates, with ongoing uncertainty in the U.K. market.
Gross Margin Expansion: Modest gross margin expansion expected in 2026 due to product and geographic mix and cost savings initiatives.
Operating Expenses: R&D expenses projected to grow in low teens on an organic basis and mid-teens factoring in PFA milestone payments. SG&A spending expected to grow below top-line growth rates.
Adjusted EBITDA and Net Income: Reaffirmed 2026 adjusted EBITDA guidance of $80 million to $82 million and full-year net income, with adjusted earnings per share of $0.09 to $0.15.
Cash Generation: Anticipates positive cash generation for 2026, with a net cash burn in Q1 followed by positive cash generation for the remainder of the year.
Clinical Trials and Product Development: Plans to complete device and generate development for dual energy EnCompass Clamp in preparation for a clinical trial. BoxX-NoAF and LeAAPS trials to continue, with results awaited for LeAAPS.
Long-Term Financial Targets: Committed to double-digit revenue growth towards a $1 billion revenue goal by 2030, with over 20% adjusted EBITDA margin.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are your thoughts on a competitor entering the market and its impact on your position?
A:The CEO views the competitor's entry positively as it validates the market and highlights its growth potential. The company has established a leadership position with over 750,000 implants and a safety rate of 0.07. They continue to innovate with new products like FLEX-Mini and PRO Mini, and have a new product planned for 2027. The LeAAPS trial with 6,573 patients is ongoing, and the company is confident in its differentiation and market position.
Q:Has there been any change in the timeline for LeAAPS trial data release?
A:The company will not release data at 50% or 75% event rates but has received positive feedback from the DSMB to continue the trial. Final results will be available at 100% of events.
Q:How does the new competitive entry in the Clip business affect your guidance for the year?
A:The CFO stated that the guidance for 2026 already factored in mild competitive pressures. The company remains confident in its 12%-14% growth guidance and is focused on spreading adoption of the FLEX-Mini Clip.
Q:Why was the Clip business softer than expected this quarter, particularly in the U.S.?
A:The softness was due to a decline in minimally invasive Clip sales, down about 6%. This was attributed to variability in the Hybrid ablation business and strong adoption of the PRO Mini product in the previous quarter. Open appendage management showed high teens growth for the quarter.
Q:Did the conclusion of enrollment in the LeAAPS trial impact the AtriClip business?
A:The company was paid for devices used in the trial, but the volume was minimal and not significant to any one quarter. Some surgeons who believe in prophylactic treatment may have offset revenue losses by enrolling in the trial.
Q:Are there any new versions or enhancements planned for the EnCompass product in the interim?
A:No new product iterations are planned. The company is focused on marketing and training for the current EnCompass Clamp, which has shown excellent results with procedure times under 10 minutes and 90% success at 1 year in a recent study.
Q:Can you size the part of the U.S. appendage management business that might compete with new entrants?
A:The company has not provided specific guidance but highlighted its strong position in the valvular market and its built-in advantages, such as combining AtriClip with ablation devices. The CABG market is a greenfield opportunity where the company is the exclusive player.
Q:Will there be R&D leverage this year as trial costs change?
A:Yes, there will be R&D leverage due to the conclusion of enrollment in the LeAAPS trial, though patient follow-up continues. The BoxX-NoAF trial will see strong enrollment, but its smaller size and different design will result in natural leverage.
Q:Is the 14% adjusted EBITDA guidance for 2026 conservative?
A:The CFO expects a step down from the 14% achieved in Q4 2025 but anticipates exceeding the 2028 goal in the near term. The company is focused on investing in clinical trials and product development to meet market needs.
Q:How many patients were treated with EnCompass in 2025, and what is the penetration relative to the total opportunity?
A:Globally, 50,000 patients were treated with EnCompass in 2025, out of a total opportunity of 2 million cardiac surgery patients. The market remains significantly underpenetrated.
Q:What impact did U.K. budget issues have on international sales?
A:The U.K. budget issues primarily impacted pain management devices and stand-alone AFib treatments, which are elective procedures. Open cardiac procedures were less affected. The U.K. market dropped from a $4 million run rate per quarter to just over $1 million in Q4 2025.
Q:What is the status of the cryoXT rollout?
A:The rollout is deliberate, focusing on learning and training with new surgeons in vascular and orthopedic areas. The company expects to expand the rollout by mid-2026 after gathering feedback and ensuring proper training.
Q:What is the update on the PFA program and its trial timeline?
A:The third milestone payment of $4 million was pushed to 2026, but the program remains on track. First-in-human use showed good results, and the clinical trial design timeline remains unchanged.
Q:What is the current state of the CONVERGE program?
A:The program is seeing some sites return and new sites onboard, but not enough to commit to growth numbers. The company is optimistic but cautious about the program's trajectory.
Q:How long do reps stay in accounts for pain management expansion?
A:Reps stay until the account completes 10-15 cases and establishes proper protocols, typically around 3 months. Most reps already have accounts using the product.
Q:What is the runway for CABG penetration and implanting physicians from new trials?
A:CABG penetration is under 10% when including non-AFib patients, with significant growth potential. New trials like BoxX-NoAF are expected to increase exposure and adoption among implanting physicians.
Q:What is preventing competitors from using their products prophylactically post-cardiac surgery before LeAAPS data is available?
A:The company believes its superior products, extensive clinical evidence, and experienced field team provide a competitive advantage. It also anticipates market growth with new entrants but expects to maintain a strong position.
Q:Review of Unclear Management Responses
A:Management avoided providing specific data on the timeline for LeAAPS trial data release, stating only that they receive a thumbs-up from the DSMB without releasing interim data. They also did not provide specific guidance on the size of the U.S. appendage management business that might compete with new entrants, instead discussing general market dynamics and their competitive advantages.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AtriClip FLEX
BoxX NoAF
Clamp
FLEX Mini
FLEX device
LeAAPS
MIS appendage
Research development
SGA
UK
appendage device
cash generation
complication
cryoSPHERE MAX
device adoption
expansion
flexibility
franchise pressure
head count
improvement loss
income
increase basis
leverage RD
milestone payment
pain
payment charge
pressure Hybrid
procedure treatment
product AtriClip
quality metric
share cash
step
teen
treatment quality
value Hybrid
ATRC Transcript
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
Positive2-17
The earnings call summary reveals strong financial performance, product development, and market expansion, particularly with the EnCompass Clamp and AtriClip devices. The Q&A section highlights challenges like U.K. budget issues but emphasizes strategic investments and clinical trials. Despite some softer Clip sales, the company's guidance remains optimistic, and increased R&D leverage is expected. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-10
AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call reflects strong product development, market expansion, and optimistic guidance, with new launches and international growth. Adjusted EBITDA guidance was raised, indicating financial health. The Q&A highlighted sustained growth in key segments and strategic focus on underpenetrated markets. While some uncertainties remain, the overall sentiment is positive, with a market cap indicating potential for significant stock movement.
ATRC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
